2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024 PMID: 39495965, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesity
2020
Mindfulnes-Based Stress Reduction for Older Couples with Metabolic Syndrome: a Pilot Randomized Controlled Trial
Monin JK, Sperduto C, Manigault AW, Dutton A, Clark M, Jastreboff A. Mindfulnes-Based Stress Reduction for Older Couples with Metabolic Syndrome: a Pilot Randomized Controlled Trial. Mindfulness 2020, 11: 917-927. PMID: 33343762, PMCID: PMC7748069, DOI: 10.1007/s12671-019-01301-9.Peer-Reviewed Original ResearchMetabolic syndromePhysical functioningIntervention effectsWait-list control armPost-intervention visitTerms of efficacySignificant intervention effectsMethodsA pilotBlood pressureClinic visitsWaist circumferenceControlled TrialsControl armPreliminary effectsSelf-reported stressSyndromeMBSR sessionsStress reductionTime pointsResultsIn termsGreater increaseOlder married couplesMental functioningMindfulness programBiological effects